Stemcentrx, a startup with funding from billionaire tech investor Peter Thiel, just came out of stealth at a $5 billion valuation, the Wall Street Journal reports.
In August the company raised a $250 million round at a $5 billion valuation, according to the Journal.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Stemcentrx was “largely unknown outside biotechnology circles” prior to emerging from stealth operation, according to the Journal.
The startup wants to cure cancer by killing cancer stem cells — the cells that spread cancer through the human body and resist cancer treatments.
According to the Journal Stemcentrx has five drugs in clinical trials. By combining cancer stem cell-targeted agents with chemotherapy, they hope to improve survival in patients with various tumors.
Peter Thiel’s Founders Fund and Artis Ventures are among Stemcentrx’s investors. And Founders Fund’s investment in Stemcentrx is the biggest the VC firm has ever made, the Journal reports.
Peter Thiel’s “fight against death” has been well-documented. His Breakout Labs funds “radical science” and “bold ideas, ” including ways to cool organs to preserve them and projects that grow bones from stem cells.
Thiel thinks that the “great enemy” of humanity is death. “I believe that evolution is a true account of nature, ” he told the Washington Post. “But I think we should try to escape it or transcend it in our society.”
